Darunavir plasma level in HIV overweight patients

Purpose of the study Darunavir (DRV) boosted with ritonavir is now regularly used in HIV infection. With an increasing population of HIV‐infected patients receiving antiretroviral therapy and having overweight problems we decided to conduct a transversal study on DRV plasma concentration in overweight patients. Methods Measures of drug plasma level were proposed to all patients having their routine blood test between 2010 and 2011 in our outpatient HIV clinic. With their consent they were included in our transversal study. DRV plasma concentrations (C12 h=12±3 hours) were determined using HPLC coupled with photodiode array detection (limit of quantification 0.05 mg/L), with DRV C12 h=1.3 mg/L and 0.55 (IC50) as target levels. Weight and height were also measured to calculate body mass index (BMI). Results We included 52 patients; 35 women and 17 men, mean age was 40 (±8.8). Majority of them (62%) were African patients. The median CD4 cell count was: 387 [297–551]. The viral load was